Evidence for tumour necrosis factor/cachectin production in cancer
F Balkwill, F Burke, D Talbot, J Tavernier, R Osborne… - The Lancet, 1987 - Elsevier
F Balkwill, F Burke, D Talbot, J Tavernier, R Osborne, S Naylor, H Durbin, W Fiers
The Lancet, 1987•ElsevierLabile tumour-necrosis-factor-like (TNF) activity was detected by means of an enzyme-linked
immunosorbent assay in 50% of 226 freshly obtained serum samples from cancer patients
with active disease. In contrast, only 3% of 32 samples from normal subjects and 18% of 39
samples from cancer patients with no clinically evident disease were positive for this factor,
with low levels of activity. Greater proportions of serum samples from patients with ovarian or
oat-cell carcinoma were positive (69% and 63%) than those from patients with lymphoma …
immunosorbent assay in 50% of 226 freshly obtained serum samples from cancer patients
with active disease. In contrast, only 3% of 32 samples from normal subjects and 18% of 39
samples from cancer patients with no clinically evident disease were positive for this factor,
with low levels of activity. Greater proportions of serum samples from patients with ovarian or
oat-cell carcinoma were positive (69% and 63%) than those from patients with lymphoma …
Abstract
Labile tumour-necrosis-factor-like (TNF) activity was detected by means of an enzyme-linked immunosorbent assay in 50% of 226 freshly obtained serum samples from cancer patients with active disease. In contrast, only 3% of 32 samples from normal subjects and 18% of 39 samples from cancer patients with no clinically evident disease were positive for this factor, with low levels of activity. Greater proportions of serum samples from patients with ovarian or oat-cell carcinoma were positive (69% and 63%) than those from patients with lymphoma (26%). RNA preparations from peripheralblood mononuclear cells and solid tumours were probed with TNF complementary DNA; evidence of TNF messenger RNA was found in 8 of 11 samples of peripheralblood mononuclear cells from cancer patients, but only 1 of 8 normal subjects, and in 2 of 6 colorectal tumours. As yet the inducing stimulus and the clinical significance of TNF production in cancer are nto understood.
Elsevier
